LAS VEGAS, Dec. 15 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (BULLETIN BOARD: SKVI) (Website: http://www.skinvisible.com/ ) through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc. announces that its patented Antimicrobial Hand Sanitizer demonstrated a greater than 99% kill in laboratory studies against the Influenza A virus.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO )
"Our studies performed at an FDA compliant laboratory confirm that our antimicrobial hand sanitizer product may help in preventing the spread of the Influenza A virus caused from hand to hand and surface to hand contact," says Skinvisible's CEO Terry Howlett.
Manufactured for and marketed by Michigan based Dermal Defense, Inc., this antimicrobial hand sanitizer incorporates Skinvisible's proprietary Invisicare(R) polymer delivery system. Notable, proven advantages of the formulation include its ability to adhere to the skin, thereby forming a protective bond. It resists both wash-off and perspiration while holding the active ingredient Triclosan on the skin for extended periods of time.
The product, marketed as Dermal Defense offers the added advantage of being alcohol-free. "Alcohol-based sanitizers typically provide instant protection but offer no long-term persistence," says Howlett. "These products require frequent reapplication, which is inconvenient for most people and because alcohol dries the skin, it can cause adverse reactions." Although proven to be effective on its own, Howlett notes that Dermal Defense is specifically designed to be a complementary adjunct to hand washing rather than a replacement.
The simplest way to avoid the flu is to stay away from crowds during an epidemic but this is easier said than done. "By incorporating Dermal Defense Antimicrobial Hand Sanitizer into a daily hygiene regime, one may reduce the risk of contracting Influenza A and other serious viral and bacterial infections," says Howlett. "It is especially recommended for people who regularly frequent schools, hospitals, athletic facilities, airports, shopping centers and other large public facilities."
The product is available commercially at Dermal Defense http://www.dermaldefense.com/ ) and through their exclusive distributor Galls Inc., "Americas Premier Authority in Public Safety Equipment" ( http://www.galls.com/ keyword search dermal defense or toll free at 1-800-477-7766).
Headquartered in Las Vegas, Nevada, Skinvisible, Inc. is focused on the development of innovative topical polymer-based delivery systems and related technologies incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymers into stable water emulsions. Skinvisible's primary marketing and sales objectives are to license its technologies and/or sell its delivery systems to provide enhanced product performance for established brand manufacturers and providers of prescription, over-the-counter, cosmetic, and skincare products. In addition Skinvisible formulates and manufactures products for private label customers.
This press release contains "forward looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports that will be on file with the US Securities and Exchange Commission (including but not limited to the report on Form 10-QSB for the quarter ending September 30, 2003).
For Corp. Info. Contact: T. Howlett - Skinvisible, Inc. - Ph. (702) 433-7154 / Fax (702) 433-7192 / Email: terry@skinvisible.com
For Media Info. Contact: Tommi Hanley - Thompson Lloyd Communications - Ph. (250) 860- 9959 / Email: tommi.tlc@shaw.ca
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comSkinvisible, Inc.CONTACT: T. Howlett of Skinvisible, Inc., +1-702-433-7154,fax +1-702-433-7192, terry@skinvisible.com; or Media, Tommi Hanleyof Thompson Lloyd Communications, +1-250-860-9959, tommi.tlc@shaw.ca
Web site: http://www.galls.com/
Web site: http://www.dermaldefense.com/
Web site: http://www.skinvisible.com/